OTCMKTS:TRPXD

Therapix Biosciences Competitors

$5.98
-3.10 (-34.14 %)
(As of 11/11/2020)
Add
Compare
Today's Range
$5.50
Now: $5.98
$5.98
50-Day Range
$5.98
MA: $7.59
$9.19
52-Week Range
$2.75
Now: $5.98
$22.40
Volume900 shs
Average Volume1,852 shs
Market Capitalization$299,000.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Therapix Biosciences (OTCMKTS:TRPXD) Vs. WWHC, IMUC, CDXI, ETST, MLNTQ, and AKAOQ

Should you be buying TRPXD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Therapix Biosciences, including W World (WWHC), ImmunoCellular Therapeutics (IMUC), Cardax (CDXI), Earth Science Tech (ETST), Melinta Therapeutics (MLNTQ), and Achaogen (AKAOQ).

W World (OTCMKTS:WWHC) and Therapix Biosciences (OTCMKTS:TRPXD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Valuation & Earnings

This table compares W World and Therapix Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
W WorldN/AN/AN/AN/AN/A
Therapix BiosciencesN/AN/A$-4,790,000.00N/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for W World and Therapix Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
W World0000N/A
Therapix Biosciences0000N/A

Profitability

This table compares W World and Therapix Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
W WorldN/AN/AN/A
Therapix BiosciencesN/AN/AN/A

Institutional and Insider Ownership

0.1% of W World shares are held by institutional investors. Comparatively, 14.3% of Therapix Biosciences shares are held by institutional investors. 61.1% of W World shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Therapix Biosciences (OTCMKTS:TRPXD) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Valuation and Earnings

This table compares Therapix Biosciences and ImmunoCellular Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Therapix BiosciencesN/AN/A$-4,790,000.00N/AN/A
ImmunoCellular TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Therapix Biosciences and ImmunoCellular Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Therapix Biosciences0000N/A
ImmunoCellular Therapeutics0000N/A

Profitability

This table compares Therapix Biosciences and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Therapix BiosciencesN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/AN/A

Institutional and Insider Ownership

14.3% of Therapix Biosciences shares are held by institutional investors. 3.3% of ImmunoCellular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Therapix Biosciences (OTCMKTS:TRPXD) and Cardax (OTCMKTS:CDXI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Profitability

This table compares Therapix Biosciences and Cardax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Therapix BiosciencesN/AN/AN/A
Cardax-891.77%N/A-297.64%

Analyst Recommendations

This is a summary of recent recommendations for Therapix Biosciences and Cardax, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Therapix Biosciences0000N/A
Cardax0000N/A

Institutional and Insider Ownership

14.3% of Therapix Biosciences shares are held by institutional investors. Comparatively, 8.7% of Cardax shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Therapix Biosciences and Cardax's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Therapix BiosciencesN/AN/A$-4,790,000.00N/AN/A
Cardax$710,000.002.35$-5,090,000.00N/AN/A

Therapix Biosciences has higher earnings, but lower revenue than Cardax.

Summary

Therapix Biosciences beats Cardax on 4 of the 5 factors compared between the two stocks.

Earth Science Tech (OTCMKTS:ETST) and Therapix Biosciences (OTCMKTS:TRPXD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Earth Science Tech and Therapix Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Earth Science Tech-1,750.31%N/A-2,929.76%
Therapix BiosciencesN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Earth Science Tech and Therapix Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Earth Science Tech0000N/A
Therapix Biosciences0000N/A

Institutional & Insider Ownership

14.3% of Therapix Biosciences shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Earth Science Tech and Therapix Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Earth Science Tech$530,000.003.14$-1,200,000.00N/AN/A
Therapix BiosciencesN/AN/A$-4,790,000.00N/AN/A

Earth Science Tech has higher revenue and earnings than Therapix Biosciences.

Summary

Therapix Biosciences beats Earth Science Tech on 3 of the 5 factors compared between the two stocks.

Melinta Therapeutics (OTCMKTS:MLNTQ) and Therapix Biosciences (OTCMKTS:TRPXD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Profitability

This table compares Melinta Therapeutics and Therapix Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Melinta TherapeuticsN/AN/AN/A
Therapix BiosciencesN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Melinta Therapeutics and Therapix Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Melinta Therapeutics0000N/A
Therapix Biosciences0000N/A

Earnings and Valuation

This table compares Melinta Therapeutics and Therapix Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Melinta Therapeutics$96.43 million0.02$-157,190,000.00N/AN/A
Therapix BiosciencesN/AN/A$-4,790,000.00N/AN/A

Therapix Biosciences has lower revenue, but higher earnings than Melinta Therapeutics.

Institutional and Insider Ownership

14.3% of Therapix Biosciences shares are owned by institutional investors. 60.3% of Melinta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Therapix Biosciences (OTCMKTS:TRPXD) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares Therapix Biosciences and Achaogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Therapix BiosciencesN/AN/AN/A
AchaogenN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and price targets for Therapix Biosciences and Achaogen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Therapix Biosciences0000N/A
Achaogen0000N/A

Valuation & Earnings

This table compares Therapix Biosciences and Achaogen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Therapix BiosciencesN/AN/A$-4,790,000.00N/AN/A
Achaogen$8.73 million0.14$-186,510,000.00N/AN/A

Therapix Biosciences has higher earnings, but lower revenue than Achaogen.

Institutional and Insider Ownership

14.3% of Therapix Biosciences shares are owned by institutional investors. Comparatively, 0.0% of Achaogen shares are owned by institutional investors. 7.8% of Achaogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


Therapix Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
WWHC
W World
0.8$6.09-4.8%$1.80 millionN/A0.00High Trading Volume
Gap Up
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.50-25.8%$1.76 millionN/A0.00Gap Up
Cardax logo
CDXI
Cardax
0.0$2.10-4.8%$1.67 million$710,000.000.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03-7.0%$1.54 million$530,000.000.00Gap Down
MLNTQ
Melinta Therapeutics
0.2$0.11-7.9%$1.51 million$96.43 million0.00Gap Up
Achaogen logo
AKAOQ
Achaogen
0.6$0.02-12.2%$1.30 million$8.73 million0.00
AOLS
Aeolus Pharmaceuticals
0.8$0.01-15.4%$1.19 millionN/A0.00Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05-388.2%$1.12 millionN/A-0.57Upcoming Earnings
High Trading Volume
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.24-4.8%$1.12 millionN/A0.00
ATRX
Adhera Therapeutics
0.0$0.09-17.6%$1.11 million$250,000.000.00Gap Up
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04-14.9%$1.08 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.01-1.4%$1.05 millionN/A0.00
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.05-16.9%$1.03 millionN/A0.00Gap Down
SPHS
Sophiris Bio
0.1$0.03-8.8%$1.01 millionN/A0.00Gap Down
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-11.0%$996,000.00N/A0.00Gap Down
PXYN
Praxsyn
0.6$0.00-25.0%$848,000.00N/A0.00Gap Up
STLT
Spotlight Innovation
0.5$0.02-55.6%$772,000.00N/A0.00Gap Down
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03-29.2%$771,000.00N/A0.00
SKVI
Skinvisible
0.7$0.15-0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-16.0%$572,000.00$1.90 million0.00
BSPM
Biostar Pharmaceuticals
0.0$0.17-12.1%$436,000.00N/A0.00Gap Up
HSTC
HST Global
0.8$0.07-108.3%$378,000.00N/A0.00High Trading Volume
Gap Down
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02-25.3%$366,000.00N/A0.00Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00Gap Up
WDBG
Woodbrook Group
0.0$1.48-14.2%$207,000.00N/A0.00Gap Down
ROSGQ
Rosetta Genomics
0.0$0.07-3.7%$119,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02-30.0%$118,000.00$20,000.000.00Gap Down
PZRXQ
PhaseRx
0.2$0.01-21.7%$108,000.00N/A0.00Gap Down
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00-150.0%$81,000.00N/A0.00Gap Up
ALSE
Alseres Pharmaceuticals
0.0$6.00-0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00-0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02-1.6%$9,000.00$110,000.000.00
Acusphere logo
ACUS
Acusphere
0.0$0.03-1.8%$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.09-8.1%$0.00N/A0.00High Trading Volume
Gap Up
AOBI
American Oriental Bioengineering
0.4$1.50-158.7%$0.00N/A0.00Gap Up
ARYX
ARYx Therapeutics
0.0$0.02-27.3%$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01-14.8%$0.00N/A0.00Gap Up
CBPI
China Botanic Pharmaceutical
0.0$0.07-0.0%$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01-0.0%$0.00N/A0.00Gap Down
China Health Industries logo
CHHE
China Health Industries
0.4$0.49-50.8%$0.00$9.93 million8.13Gap Down
DDXSQ
Diadexus
0.0$0.00-0.0%$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04-14.3%$0.00N/A0.00Gap Down
FTCY
Global Future City
0.5$0.05-1.8%$0.00N/A0.00High Trading Volume
GLSI
Greenwich LifeSciences
1.7$53.60-5.8%$0.00N/A0.00High Trading Volume
Gap Down
HRBR
Harbor Diversified
0.0$1.12-4.5%$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00-0.0%$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00-33.3%$0.00N/A0.00High Trading Volume
Gap Down
MBVXQ
MabVax Therapeutics
0.0$0.02-8.7%$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.05-5.8%$0.00N/A0.00Gap Down
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.